It is note worthy that the RVVTF repurposed Bucillamine drug trial for Covid19 is also approved for Liver transplant orphan drug trials.
And kids are dying of Liver disease caused by Covid19 according the news this week.
Does COVID-19 damage the liver?
Some patients hospitalized for COVID-19 have had increased levels of liver enzymes — such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Increased levels of liver enzymes can mean that a person’s liver is at least temporarily damaged. People with cirrhosis [liver scarring] may be at increased risk of COVID-19. Some studies have shown that people with pre-existing liver disease (chronic liver disease, cirrhosis, or related complications) who were diagnosed with COVID-19 are at higher risk of death than people without pre-existing liver disease.
===========
Multi-Country – Acute, severe hepatitis of unknown origin in children
23 April 2022 a month ago/
???????
Please note that this Disease Outbreak News has been revised to correct the WHO working case definition that was published on 23 April 2022.
Outbreak at a glance:
Since the WHO Disease Outbreak News on Acute hepatitis of unknown aetiology – the United Kingdom of Great Britain and Northern Ireland was published on 15 April 2022, there have been continuing further reports of cases of acute hepatitis of unknown origin among young children. It is not yet clear if there has been an increase in hepatitis cases, or an increase in awareness of hepatitis cases that occur at the expected rate but go undetected. While adenovirus is a possible hypothesis, investigations are ongoing for the causative agent.
Outbreak overview
As of 21 April 2022, at least 169 cases of acute hepatitis of unknown origin have been reported from 11 countries in the WHO European Region and one country in the WHO Region of the Americas (Figure 1). Cases have been reported in the United Kingdom of Great Britain and Northern Ireland (the United Kingdom) (114), Spain (13), Israel (12), the United States of America (9), Denmark (6), Ireland (<5), The Netherlands (4), Italy (4), Norway (2), France (2), Romania (1), and Belgium (1).
Figure 1. Distribution of cases of acute severe hepatitis of unknown origin by country, as of 23 April 2022.
Cases are aged 1 month to 16 years old. Seventeen children (approximately 10%) have required liver transplantation; at least one death has been reported.
The clinical syndrome among identified cases is acute hepatitis (liver inflammation) with markedly elevated liver enzymes. Many cases reported gastrointestinal symptoms including abdominal pain, diarrhoea and vomiting preceding presentation with severe acute hepatitis, and increased levels of liver enzymes (aspartate transaminase (AST) or alanine aminotransaminase (ALT) greater the 500 IU/L) and jaundice. Most cases did not have a fever. The common viruses that cause acute viral hepatitis (hepatitis viruses A, B, C, D and E) have not been detected in any of these cases. International travel or links to other countries based on the currently available information have not been identified as factors.
Adenovirus has been detected in at least 74 cases, and of the number of cases with information on molecular testing, 18 have been identified as F type 41. SARS-CoV-2 was identified in 20 cases of those that were tested. Furthermore, 19 were detected with a SARS-CoV-2 and adenovirus co-infection.
The United Kingdom, where the majority of cases have been reported to date, has recently observed a significant increase in adenovirus infections in the community (particularly detected in faecal samples in children) following low levels of circulation earlier in the COVID-19 pandemic. The Netherlands also reported concurrent increasing community adenovirus circulation.
Nevertheless, due to enhanced laboratory testing for adenovirus, this could represent the identification of an existing rare outcome occurring at levels not previously detected that is now being recognized due to increased testing.
Public health response
Further investigations are ongoing in countries that have identified cases and include more detailed clinical and exposure histories, toxicology testing (i.e. environmental and food toxicity testing), and additional virological/microbiological tests. Affected countries have also initiated enhanced surveillance activities.
WHO and ECDC are supporting countries with the ongoing investigations and collecting information from the countries reporting cases. All available information is further disseminated by countries through their Hepatitis Networks and clinical organisations such as the European Association for the Study of the Liver, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN).
For cases in Europe, joint WHO/ECDC data collection will be established using The European Surveillance System (TESSy).
Guidance derived by the United Kingdom Health Security Agency has been issued to affected countries to support a thorough investigation of suspected cases.
WHO risk assessment
The United Kingdom first reported an unexpected significant increase in cases of severe acute hepatitis of unknown origin in young, generally previously healthy children. An unexpected increase of such cases has now been reported by several other countries – notably Ireland and the Netherlands.
While adenovirus is currently one hypothesis as the underlying cause, it does not fully explain the severity of the clinical picture. Infection with adenovirus type 41, the implicated adenovirus type, has not previously been linked to such a clinical presentation. Adenoviruses are common pathogens that usually cause self-limited infections. They spread from person-to-person and most commonly cause respiratory illness, but depending on the type, can also cause other illnesses such as gastroenteritis (inflammation of the stomach or intestines), conjunctivitis (pink eye), and cystitis (bladder infection). There are more than 50 types of immunologically distinct adenoviruses that can cause infections in humans. Adenovirus type 41 typically presents as diarrhea, vomiting, and fever, often accompanied by respiratory symptoms. While there have been case reports of hepatitis in immunocompromised children with adenovirus infection, adenovirus type 41 is not known to be a cause of hepatitis in otherwise healthy children.
Factors such as increased susceptibility amongst young children following a lower level of circulation of adenovirus during the COVID-19 pandemic, the potential emergence of a novel adenovirus, as well as SARS-CoV-2 co-infection, need to be further investigated. Hypotheses related to side effects from the COVID-19 vaccines are currently not supported as the vast majority of affected children did not receive COVID-19 vaccination. Other infectious and non-infectious explanations need to be excluded to fully assess and manage the risk.
With continued new notifications of recent onset cases, at least in the United Kingdom, together with more extensive case searching, it is very likely that more cases will be detected before the cause can be confirmed and more specific control and prevention measures can be implemented.
WHO is closely monitoring the situation and working with the United Kingdom health authorities, other Member States and partners.
WHO advice
Further work is required to identify additional cases, both in currently affected countries and elsewhere. The priority is to determine the cause of these cases to further refine control and prevention actions. Common prevention measures for adenovirus and other common infections involve regular hand washing and respiratory hygiene.
Member States are strongly encouraged to identify, investigate and report potential cases fitting the case definition1. Epidemiological and risk factor information should be collected and submitted by Member States to WHO and partner agencies through agreed reporting mechanisms. Any epidemiological links between or among the cases might provide clues for tracking the source of illness. Temporal and geographical information about the cases, as well as their close contacts should be reviewed for potential risk factors.
WHO recommends that testing of blood (with initial anecdotal experience that whole blood is more sensitive than serum), serum, urine, stool, and respiratory samples, as well as liver biopsy samples (when available) should be undertaken, with further virus characterization including sequencing. Other infectious and non-infectious causes need to be thoroughly investigated.
WHO does not recommend any restriction on travel and/or trade with the United Kingdom, or any other country where cases are identified, based on the currently available information.
1WHO working case definition:
Confirmed: N/A at presentProbable: A person presenting with an acute hepatitis (non hepA-E*) with serum transaminase >500 IU/L (AST or ALT), who is 16 years and younger, since 1 October 2021Epi-linked: A person presenting with an acute hepatitis (non hepA-E*) of any age who is a close contact of a probable case, since 1 October 2021.*If hepatitis A-E serology results are awaited, but other criteria met, these can be reported and will be classified as “pending classification”. Cases with other explanations for their clinical presentation are discarded.
Further information
UK Health Security Agency (UKHSA), Increase in hepatitis (liver inflammation) cases in children under investigation UKHSA Guidance note including recommended tests European Centre for Disease Prevention and Control, Update: Hepatitis of unknown origin in children WHO Disease Outbreak News; Acute hepatitis of unknown aetiology - the United Kingdom of Great Britain and Northern Ireland. US Centres for Disease Control Health Advisory, Recommendations for Adenovirus Testing and Reporting of Children with Acute Hepatitis of Unknown Etiology CDC Alerts Providers to Hepatitis Cases of Unknown OriginCitable reference: World Health Organization (23 April 2022). Disease Outbreak News; Multi-Country – Acute, severe hepatitis of unknown origin in children. Available at: who.int |
